QLS31905 not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
7 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“QLS31905 will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.”In the company’s words, NCT07716449 on ClinicalTrials.gov
Tested for
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer, Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Main trialPhase 3
“This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 , Her-2 Negtive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.”In the company’s words, NCT07716449 on ClinicalTrials.gov

Other drugs for Gastric or Gastroesophageal Junction Adenocarcinoma

All 196 drugs for Gastric or Gastroesophageal Junction Adenocarcinoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Sep 2028 QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
Phase 3Recruiting Dec 2028 A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Phase 2Not yet recruiting 30 Jun 2026 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Phase 2Not yet recruiting Oct 2026 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Phase 2Not yet recruiting Dec 2026 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/2Unknown Oct 2024 A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
Phase 1Unknown 31 Dec 2022 A Study of QLS31905 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow QLS31905

Following is part of Solo: you see every change to QLS31905 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in